Literature DB >> 22374080

Pharmacovigilance practice and risk control of Traditional Chinese Medicine drugs in China: current status and future perspective.

Li Zhang1, Jingbo Yan, Xinmin Liu, Zuguang Ye, Xiaohui Yang, Ronald Meyboom, Kelvin Chan, Debbie Shaw, Pierre Duez.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Traditional Chinese Medicine (TCM), including Traditional Chinese Medicine drugs (TCM drugs), has been playing a very important role in health protection and disease control for thousands of years in China. Relying on natural products, mainly of herbal origin, used either as raw materials for decoction, as prepared herbal medicines or as formulated traditional medicines, TCM is still widely accepted by Chinese people, especially for chronic diseases treatment. This extensive use warrants safety measures and so TCM drug safety monitoring and risk management are becoming increasingly important tasks for the Chinese State Food and Drug Administration (SFDA).
METHODS: The Adverse Drug Reaction (ADR) monitoring system in China was established both for western and TCM drugs in 1989 as a voluntary reporting system with a National Center collecting and compiling reports. Serious or multi-case reports on individual TCM drug or formulated products are detailed in the Chinese ADR Information Bulletin to inform the public and Drug Administrative authorities for risk management.
RESULTS: About 10-15% of the ADR reports received by the National Center are related to TCM drugs and mainly pertaining to the formulated products. In certain cases, the suspension of a particular TCM preparation is decided by SFDA China.
CONCLUSION: The model of safety monitoring and risk management of TCM drugs is still under exploration. Indeed, the characteristics and risk factors associated with these drugs require both proper understanding and control of the risk by strengthening standardization of clinical applications, basic science research, quality control in manufacturing, exploration of the actives monitoring methodology and enhancement of international communication and cooperation.
Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22374080     DOI: 10.1016/j.jep.2012.01.058

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  48 in total

1.  Adverse events attributed to traditional Korean medical practices: 1999-2010.

Authors:  Hyeun-Kyoo Shin; Soo-Jin Jeong; Myeong Soo Lee; Edzard Ernst
Journal:  Bull World Health Organ       Date:  2013-05-31       Impact factor: 9.408

2.  Detecting drug-herbal interaction using a spontaneous reporting system database: an example with benzylpenicillin and qingkailing injection.

Authors:  Haona Li; Jianxiong Deng; Zhihua Yue; Yiexiang Zhang; He Sun
Journal:  Eur J Clin Pharmacol       Date:  2015-07-11       Impact factor: 2.953

Review 3.  An overview on adverse drug reactions to traditional Chinese medicines.

Authors:  Kelvin Chan; Hongwei Zhang; Zhi-Xiu Lin
Journal:  Br J Clin Pharmacol       Date:  2015-05-19       Impact factor: 4.335

Review 4.  Pharmacovigilance in China: development and challenges.

Authors:  Ying Zhao; Tiansheng Wang; Guangyao Li; Shusen Sun
Journal:  Int J Clin Pharm       Date:  2018-07-26

Review 5.  Biological activity and toxicity of the Chinese herb Magnolia officinalis Rehder & E. Wilson (Houpo) and its constituents.

Authors:  Mélanie Poivre; Pierre Duez
Journal:  J Zhejiang Univ Sci B       Date:  2017 Mar.       Impact factor: 3.066

6.  Pharmacovigilance in China: current situation, successes and challenges.

Authors:  Li Zhang; Lisa Y L Wong; Ying He; Ian C K Wong
Journal:  Drug Saf       Date:  2014-10       Impact factor: 5.606

7.  A great honor and a huge challenge for China: You-you TU getting the Nobel Prize in Physiology or Medicine.

Authors:  Da Yuan; Xue Yang; Jun-Chao Guo
Journal:  J Zhejiang Univ Sci B       Date:  2016-05       Impact factor: 3.066

8.  Traditional Chinese medicine and drug-induced anaphylaxis: data from the Beijing pharmacovigilance database.

Authors:  Xiaotong Li; Sydney Thai; Wenchao Lu; Shusen Sun; Huilin Tang; Suodi Zhai; Tiansheng Wang
Journal:  Int J Clin Pharm       Date:  2018-07-26

Review 9.  Herbal traditional Chinese medicine and its evidence base in gastrointestinal disorders.

Authors:  Rolf Teschke; Albrecht Wolff; Christian Frenzel; Axel Eickhoff; Johannes Schulze
Journal:  World J Gastroenterol       Date:  2015-04-21       Impact factor: 5.742

Review 10.  Safety surveillance of traditional Chinese medicine: current and future.

Authors:  Shwu-Huey Liu; Wu-Chang Chuang; Wing Lam; Zaoli Jiang; Yung-Chi Cheng
Journal:  Drug Saf       Date:  2015-02       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.